Investigational drug · Phase 3
VYD2311
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Long COVID, COVID-19 (SARS-CoV-2 Infection), COVID 19 Vaccine.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
4
Any phase or sponsor naming "VYD2311"
First trial start
2026
Jun 8, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VYD2311", any sponsor or status.
Conditions studied
As listed on its trial records.
- Long COVID
- COVID-19 (SARS-CoV-2 Infection)
- COVID 19 Vaccine
- COVID Long
- COVID-19
Approved drugs for the same conditions: COVID-19 · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VYD2311" as an intervention, largest first.
- Study of VYD2311 for the Prevention of COVID-19Pivotal-lookingActive, not recruiting
Invivyd, Inc.Industry
NCT07298434 · 1,770 participants (planned) · Start Jan 8, 2026 · Primary completion Aug 2026
Drug: VYD2311-SD; VYD2311-MD and 1 more · For: COVID-19
Sites: Long Beach, California; San Diego, California; Orlando, Florida · 20 sites in all
- Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 VaccinePivotal-lookingCompleted
Invivyd, Inc.Industry
NCT07655180 · 210 participants · Start Jun 8, 2026 · Primary completion Aug 15, 2026
Drug: COVID-19 mRNA vaccine; VYD2311 and 1 more · For: COVID-19
Sites: Overland Park, Kansas
- Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination SyndromePivotal-lookingNot yet recruiting
Invivyd, Inc.Industry
NCT07899346 · 130 participants (planned) · Start Oct 2026 · Primary completion Jun 2027
Drug: VYD2311; Placebo · For: Long COVID; COVID-19 (SARS-CoV-2 Infection); COVID 19 Vaccine and 1 more
- A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy ParticipantsActive, not recruiting
Invivyd, Inc.Industry
NCT06523153 · 40 participants (planned) · Start Aug 28, 2024 · Primary completion May 2025
Drug: VYD2311 · For: COVID-19
Sites: Joondalup, Australia
Newest research
PubMed records naming it or its code names, newest first.
- The monoclonal antibody VYD2311 potently neutralizes dominant and emerging SARS-CoV-2 variants.
Mellis IA, Wu M, Daniel K, et al. · JCI Insight 2026
Also in development for Long COVID
- NE3107bezisterimPhase 22 trials
BioVie Inc. · Long COVID, Parkinsons Disease (PD)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.